ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of ImmunoPrecise Antibodies (NASDAQ:IPA) in a research report report published on Friday,Benzinga reports. They currently have a $5.00 price objective on the stock.

Separately, Benchmark reiterated a “speculative buy” rating and set a $3.00 target price on shares of ImmunoPrecise Antibodies in a research note on Tuesday, April 1st.

ImmunoPrecise Antibodies Trading Up 7.6 %

IPA stock opened at $0.43 on Friday. ImmunoPrecise Antibodies has a one year low of $0.27 and a one year high of $1.39. The stock has a market cap of $13.40 million, a price-to-earnings ratio of -0.55 and a beta of -0.02. The company has a fifty day moving average price of $0.41 and a two-hundred day moving average price of $0.46. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.01 and a quick ratio of 0.85.

ImmunoPrecise Antibodies (NASDAQ:IPA) last announced its earnings results on Friday, March 28th. The company reported ($0.06) EPS for the quarter, hitting the consensus estimate of ($0.06). The business had revenue of $4.23 million during the quarter, compared to the consensus estimate of $6.59 million. ImmunoPrecise Antibodies had a negative net margin of 114.50% and a negative return on equity of 73.74%. Equities analysts anticipate that ImmunoPrecise Antibodies will post -0.27 EPS for the current year.

About ImmunoPrecise Antibodies

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes.